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Virus immobilisationWe present the synthesis and application of a molecule containing both the powerful inﬂuenza neur-
aminidase (NA) inhibitor phospha-oseltamivir and D-biotin, connected via an undecaethylene glycol
spacer. It inhibits inﬂuenza virus neuraminidase (from the H3N2 X31 virus) in the same range as oseltam-
ivir, with a slow off-rate, and produces a stable NA-coated surface when loaded onto streptavidin-coated
biosensors. Puriﬁed X31 virus binds to these loaded biosensors with an apparent dissociation constant in
the low picomolar range and binding of antibodies to the immobilized virus could be readily detected.
The compound is thus a potential candidate for the selective immobilization of inﬂuenza virus in inﬂu-
enza diagnosis, vaccine choice, development or testing.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Selective and effective detection, immobilization and character-
ization of inﬂuenza viruses is an essential part of a large variety of
tests and experiments in inﬂuenza diagnosis and inﬂuenza vaccine
production.1 Immobilization of viruses can be achieved in either an
unspeciﬁcmanner, for instance direct immobilization onpolystyrene
plates, or by speciﬁc binding to either immobilized anti-inﬂuenza
antibodies or to immobilized carbohydrates or glycoproteins (e.g. fet-
uin) that carry terminal sialic acid residues. The latter interaction oc-
curs mainly through the inﬂuenza virus hemagglutinin (HA) and
necessitates a high degree of multivalency (many carbohydrates
interacting with many HA’s). Antibody cross-reactivity testing
(essential in inﬂuenza vaccine selection and characterization) is cur-
rently severely dependent on the standard hemagglutination inhibi-
tion assay (HI). The HI assay involves examining the amount of
antibody (serum) needed to inhibit the non-speciﬁc cross-linking of
red blood cells by inﬂuenza virus (red blood cell cross-linking occurs
mostly via the virus HA binding to sialic acid bearing carbohydrates
on the red blood cell surface). All thesemethods, thoughwidely used,
have their individual shortcomings.2,3 Carbohydrate based immobili-
zation strategies suffer from leaching effects and variations in afﬁni-
ties of the inﬂuenza viruses for particular carbohydrates. Antibodyimmobilization can suffer similar problems, as well as competition
in binding when examining binding of antibodies/serum (a primary
use of virus immobilization). There is also a major problemwith cur-
rent H3N2 virus strains (which continues to circulate and predomi-
nates in many regions of the world) in that they have notoriously
weak binding to carbohydrate ligands via HA,3–5 meaning standard
assays (such as the HI assay) are becoming more difﬁcult to perform
and difﬁcult to interpret, thus representing an ongoing problem for
reference centres and vaccine producers.
Immobilization of inﬂuenza viruses via their surface neuramin-
idase (NA) is much less established despite inﬂuenza NA inhibitors
such as oseltamivir, zanamivir or peramivir displaying a much
stronger monovalent interaction with NA than sialic acids binding
to HA.6,7 We have designed phospha-oseltamivir–biotin conjugate
1, containing an undecaethylene glycol spacer moiety, which
inhibits NA (from H3N2 X31 virus)8 in the subnanomolar range
(Ki = 1.8 nM), similar to conjugate 2 containing only a short spacer
(Ki = 0.24 nM) and only slightly weaker than oseltamivir itself
(Ki = 0.12 nM). Compound 2, reported by us earlier,9 failed to
immobilize virus effectively when tested with streptavidin-coated
biosensors, most likely because it is unable to bind to virus and
streptavidin simultaneously (not published). This indicated the
importance of spacer type and length for the envisaged immobili-
zation (Fig. 1).
1806 H. Streicher et al. / Bioorg. Med. Chem. Lett. 24 (2014) 1805–1807Synthesis: In brief, azido derivative 3 is reduced to the aminewith
trimethyl phosphine and then coupled with O-[2-(Biotinylami-
no)ethyl]-O0-(2-carboxyethyl)undecaethylene glycol using PyBOP
(Scheme 1). The resulting protected target molecule 4 was then
deprotected in two steps using previously published procedures to
give 1. in high yield.9,10
Neuraminidase inhibition: In the well-established MUNANA
assay,11 compound 1 tested with puriﬁed N2 neuraminidase (from
the H3N2 X31 virus) gave Ki = 1.8 ± 0.4 nM (kon = 5.6  104 M1 s1,
koff = 1  104 s1 (estimated from Ki  kon)). This compares with
oseltamivir, Ki = 0.12 ± 0.3 nM (kon = 2  106 M1 s1, koff = 2.4 -
 104 s1 (estimated fromKi kon)). Hence compound1bindsmore
slowly and dissociates a little more slowly than oseltamivir, and
inhibits 15-fold more weakly, but still in the low nanomolar range.
The high afﬁnity and slow off-rate of compound 1 binding by neur-
aminidasemeans that it is highly suitable for immobilization of virus
particles on streptavidin-coated surfaces.
Surface interaction analysis: Binding of neuraminidase and virus
to compound 1 was measured on an Octet RED biolayer interfer-
ometer (Pall ForteBio Corp., Menlo Park, CA, USA). The compound
was stably immobilized on streptavidin biosensors (Pall ForteBioO(CH2)6P
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Figure 1. Phospha-oseltamivir conjugated to D-biotin with (1) and without
undecaethyleneglycol spacer (2).
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Scheme 1. Synthesis of conjugate 1.Corp., Menlo Park, CA, USA) at a concentration of 0.5 lg/ml. All
measurements were performed in 10 mM HEPES (pH 7.4),
150 mM NaCl, 3 mM EDTA and 0.005% Tween-20 at 25 C.Binding
of NA (0.1–20 nM) was measured at 25 C with a 50 min associa-
tion step. Binding of virus (1–400 pM) was measured with a
200 min association step. In both cases the response at the end
of the association step was used to determine the equilibrium dis-
sociation constant.
Puriﬁed N2 neuraminidase (from X31) bound to immobilised
compound 1, with an equilibriumdissociation constant,Kd = 3.4 nM
(see Fig. 2, upper graph), which compares well with the Ki deter-
mined in theMUNANA assay (despite standard buffers and temper-
atures being somewhat different in the different experiments). No
binding was observed for compound 2 due to the shorter linker.
Figure 2 (lower graph) shows that puriﬁed X31 virus12 binds to
compound 1 coated biosensors, with an apparent equilibrium
dissociation constant, Kd of 11 pM, a 300-fold increase in afﬁnity
compared to the binding of the puriﬁed neuraminidase due to mul-
tivalent avidity effects from binding of multiple neuraminidases on
the surface of the virus simultaneously (Fig. 2).
Virus immobilization and antibody binding: To show the potential
of the immobilization strategy using streptavidin-coated
biosensors as described above, we have demonstrated that the
binding of several different antibodies13 to immobilized X31 canFigure 2. NA binding (upper graph) and virus X31 binding (lower graph) to
streptavidin-coated biosensors loaded with compound 1.
Figure 3. Binding of monoclonal antibodies Hc73 (yellow, Kd  0.7 nM), Hc100
(green, Kd  1.5 nM) and Hc221 (purple, Kd  6.5 nM) to immobilized X31.
H. Streicher et al. / Bioorg. Med. Chem. Lett. 24 (2014) 1805–1807 1807be detected (see Fig. 3). The method therefore has the potential to
be used in examining the cross-reactivity of antibodies/sera be-
tween different virus strains, an essential part of inﬂuenza vaccine
choice, development and testing.
In conclusion, we have presented a new compound suitable to
effectively immobilize the inﬂuenza virus on streptavidin-coated
surfaces based on strong binding to the inﬂuenza NA. We believe
it has good chance to be used by laboratories charged with the task
of ﬁnding new solutions to the ongoing threat of inﬂuenza epidem-
ics and pandemics.
Supplementary data
Supplementary data (Synthetic procedures and analytical data
for compounds 1 and 4.) associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.bmcl.2014.02.
021.
References and notes
1. Gerdil, C. Vaccine 2003, 21, 1776.2. Ndiofon, W. Inﬂuenza Other Respir. Viruses 2011, 5, 206.
3. Lin, Y. P.; Gregory, V.; Collins, P.; Kloess, J.; Wharton, S.; Cattle, N.; Lackenby, A.;
Daniels, R.; Hay, A. J. Virol. 2010, 84, 6769.
4. Russel, R. J.; Stevens, D. J.; Haire, L. F.; Gamblin, S. J.; Skehel, J. J. Glycoconj. J.
2006, 23, 85.
5. Lin, Y. P.; Xiong, X.; Wharton, S. A.; Martin, S. R.; Coombs, P.; Vachieri, S.;
Christodoulou, E.; Walker, P. A.; Liu, J.; Skehel, J. J.; Gamblin, S. J.; Hay, A. J.;
Daniels, R. S.; McCauley, J. W. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 21474.
6. McKimm-Breschkin, J. L.; Colman, P. M.; Jin, B.; Krippner, G. Y.; McDonald, M.;
Reece, P. A.; Tucker, S. P.; Waddington, L.; Watson, K. G.; Wu, W.-Y. Angew.
Chem., Int. Ed. 2003, 42, 3118.
7. Kale, R. R.; Mukundan, H.; Price, D. N.; Harris, J. F.; Lewallen, D. M.; Swanson, B.
I.; Schmidt, J. G.; Iyer, S. S. J. Am. Chem. Soc. 2008, 130, 8169.
8. The strain is a standard in inﬂuenza research. http://www.uniprot.org/
taxonomy/132504.
9. Stanley, M.; Birge, M.; Carbain, B.; Martin, S. R.; Streicher, H. Org. Biomol. Chem.
2011, 9, 5625.
10. Carbain, B.; Collins, P. J.; Callum, L.; Martin, S. R.; Hay, A. J.; McCauley, J.;
Streicher, H. ChemMedChem 2009, 4, 335.
11. Collins, P. J.; Haire, L. F.; Lin, Y. P.; Liu, J.; Russell, R. J.; Walker, P. A.; Skehel, J. J.;
Martin, S. R.; Hay, A. J.; Gamblin, S. J. Nature 2008, 453, 1258.
12. Skehel, J. J.; Schild, G. C. Virology 1971, 44, 396.
13. Daniels, R. S.; Douglas, A. R.; Skehel, J. J.; Wiley, D. C.; Naeve, C. W.; Webster, R.
G.; Rogers, G. N.; Paulson, J. C. Virology 1984, 138, 174.
